Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of meeting with Analyst/Investor06-03-2024
06-03-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Change in Directorate
Please find attached letter informing change in Directorate.06-03-2024
Glenmark Life Sciences Ltd - 543322 - Post Offer Advertisement
DAM Capital Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Post Offer Advertisement under Regulation 18(12) of the SEBI (SAST) Regulations, 2011, as amended ("SEBI (SAST) Regulations") for the attention of the Public Shareholders of Glenmark Life Sciences Ltd ("Target Company").06-03-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Change in Directorate
Find attached herewith letter informing change in Directorate.06-03-2024
Glenmark Life Sciences Ltd - 543322 - General Update- Designation Of Nirma Limited As A New Promoter Of The Company.
General Update- Designation of Nirma Limited as a new Promoter of the Company.06-03-2024
Glenmark Life Sciences Ltd - 543322 - Disclosure Pursuant To Regulation 30(7) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure pursuant to regulation 30 (7) of the SEBI (LODR) Regulations, 2015 is attached.06-03-2024
Glenmark Life Sciences Ltd - 543322 - Updates on Open Offer
DAM Capital Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Offer Opening Public Announcement under Regulation 18(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI (SAST) Regulations") and Corrigendum to the Detailed Public Statement and the Letter of Offer for the attention of the Public Shareholders of Glenmark Life Sciences Ltd ("Target Company").14-02-2024
Glenmark Life Sciences: Nirma's open offer and key insights on the stock
Nirma set to acquire Glenmark Life Sciences via open offer from February 15-29; Despite offer price, investors urged to consider GLS's growth prospects14-02-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
We are enclosing herewith Monitoring Agency Report for the quarter ended 31st December 2023.13-02-2024
Glenmark Life Sciences Ltd - 543322 - Recommendations Of The Committee Of Independent Directors Under Regulation 26(7) Of The SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
Please find attached herewith newspaper publications of Recommendation of the Committee of Independent Directors under Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 201112-02-2024